Literature DB >> 14531462

Particular features of photolabile substances in tablets.

W Aman1, K Thoma.   

Abstract

Nifedipine and molsidomine tablets are extremely photolabile drug preparations, even at cool room light. Compared to solutions the light spectrum responsible for photodegradation is moved towards the long-wavelength range corresponding to the bathochromic shift of light absorption in the solid state. In the case of nifedipine tablets light up to 500 nm, especially the range between 400-420 nm, is degrading. Molsidomine tablets are affected only by ultraviolet light, but not by visible light. In both cases light penetrates less than 1 mm into the tablets. For nifedipine tablets the exact penetration depth could be determined due to the discolouration of the drug substance upon irradiation. It varied from 360 microm to 880 microm depending on the drug content. Since the decomposition products of nifedipine act as photostabilizers by spectral overlay, light penetration and photodegradation in nifedipine tablets are limited. The formation of gaseous and liquid decomposition products in molsidomine tablets enhances photodegradation. Changes of the tablet structure as well as dissolution and migration processes are discussed. Furthermore the degradation products donot photostabilize the drug substance due to the missing light absorption above 300 nm.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14531462

Source DB:  PubMed          Journal:  Pharmazie        ISSN: 0031-7144            Impact factor:   1.267


  2 in total

1.  Development of a UV-Stabilized Topical Formulation of Nifedipine for the Treatment of Raynaud Phenomenon and Chilblains.

Authors:  Ellen K Wasan; Jinying Zhao; Joshua Poteet; Munawar A Mohammed; Jaweria Syeda; Kevin Soulsbury; Jacqueline Cawthray; Amanda Bunyamin; Chi Zhang; Brian M Fahlman; Ed S Krol
Journal:  Pharmaceutics       Date:  2019-11-09       Impact factor: 6.321

2.  A Non-Invasive Method for Detection of Antihypertensive Drugs in Biological Fluids: The Salivary Therapeutic Drug Monitoring.

Authors:  Valeria Avataneo; Elvira Fanelli; Amedeo De Nicolò; Franco Rabbia; Alice Palermiti; Marco Pappaccogli; Jessica Cusato; Francesco Giuseppe De Rosa; Antonio D'Avolio; Franco Veglio
Journal:  Front Pharmacol       Date:  2022-01-05       Impact factor: 5.810

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.